Michelle J Groome1, Jocelyn Moyes2, Cheryl Cohen3, Sibongile Walaza2, Stefano Tempia4, Marthi Pretorius3, Orienka Hellferscee3, Meera Chhagan5, Sumayya Haffejee6, Halima Dawood5, Kathleen Kahn7, Ebrahim Variava8, Adam L Cohen4, Anne von Gottberg9, Nicole Wolter9, Marietjie Venter3, Shabir A Madhi10. 1. Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: groomem@rmpru.co.za. 2. Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 3. Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa. 4. Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Influenza Programme, Centers for Disease Control and Prevention-South Africa, Pretoria, South Africa. 5. Pietermaritzburg Hospital complex, University of KwaZulu-Natal, Pietermaritzburg, South Africa. 6. Pietermaritzburg Hospital complex, University of KwaZulu-Natal, Pietermaritzburg, South Africa; School of Pathology, University of KwaZulu-Natal, South Africa. 7. MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Centre for Global Health Research, Umeå University, Umeå, Sweden; INDEPTH Network, Accra, Ghana. 8. Department of Medicine, Klerksdorp Tshepong Hospital, Klerksdorp, South Africa; Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 9. Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 10. Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Abstract
BACKGROUND: Data on human metapneumovirus (HMPV)-associated severe acute respiratory illness (SARI) are limited in settings with high human immunodeficiency virus (HIV) infection prevalence. OBJECTIVES: To describe clinical characteristics and seasonality (all sites), and incidence (Soweto only) of HMPV-associated SARI among children and adults. STUDY DESIGN: Active, prospective, hospital-based, sentinel surveillance for patients hospitalised with SARI was conducted at four sites in South Africa from February 2009-December 2013. Upper respiratory tract samples were tested by multiplex real-time polymerase chain reaction assays for HMPV and other respiratory viruses. Incidence of hospitalisation, stratified by age and HIV-infection status, was calculated for one hospital with population denominators. RESULTS: HMPV was identified in 4.1% of patients enrolled, including 5.6% (593/10503) in children and 1.7% in adults (≥18 years; 119/6934). The majority of adults (84.0%) had an underlying medical condition, including HIV infection in 87/110 (79.1%). HMPV detection occurred perennially with periods of increased detection, which varied from year to year. The incidence of HMPV-associated hospitalisation in Soweto was highest in infants (653.3 per 100,000 person years; 95% confidence interval (CI) 602.2-707.6). The incidence was higher in HIV-infected persons compared to HIV-uninfected persons in age-groups 5-17 years (RR 6.0; 1.1-20.4), 18-44 years (RR 67.6; 38.0-132.6) and 45-64 years (RR 5.3; 3.4-8.3), while not differing in other age-groups. CONCLUSIONS: The burden of HMPV-associated SARI hospitalisation among adults occurred predominantly in HIV-infected persons. Among children, infants were at highest risk, with similar burden of hospitalisation in HIV-infected and HIV-uninfected children.
BACKGROUND: Data on human metapneumovirus (HMPV)-associated severe acute respiratory illness (SARI) are limited in settings with high human immunodeficiency virus (HIV) infection prevalence. OBJECTIVES: To describe clinical characteristics and seasonality (all sites), and incidence (Soweto only) of HMPV-associated SARI among children and adults. STUDY DESIGN: Active, prospective, hospital-based, sentinel surveillance for patients hospitalised with SARI was conducted at four sites in South Africa from February 2009-December 2013. Upper respiratory tract samples were tested by multiplex real-time polymerase chain reaction assays for HMPV and other respiratory viruses. Incidence of hospitalisation, stratified by age and HIV-infection status, was calculated for one hospital with population denominators. RESULTS: HMPV was identified in 4.1% of patients enrolled, including 5.6% (593/10503) in children and 1.7% in adults (≥18 years; 119/6934). The majority of adults (84.0%) had an underlying medical condition, including HIV infection in 87/110 (79.1%). HMPV detection occurred perennially with periods of increased detection, which varied from year to year. The incidence of HMPV-associated hospitalisation in Soweto was highest in infants (653.3 per 100,000 person years; 95% confidence interval (CI) 602.2-707.6). The incidence was higher in HIV-infected persons compared to HIV-uninfected persons in age-groups 5-17 years (RR 6.0; 1.1-20.4), 18-44 years (RR 67.6; 38.0-132.6) and 45-64 years (RR 5.3; 3.4-8.3), while not differing in other age-groups. CONCLUSIONS: The burden of HMPV-associated SARI hospitalisation among adults occurred predominantly in HIV-infected persons. Among children, infants were at highest risk, with similar burden of hospitalisation in HIV-infected and HIV-uninfected children.
Authors: Guy Boivin; Yacine Abed; Gilles Pelletier; Louisette Ruel; Danielle Moisan; Stéphanie Côté; Teresa C T Peret; Dean D Erdman; Larry J Anderson Journal: J Infect Dis Date: 2002-10-08 Impact factor: 5.226
Authors: Cristina O'Callaghan-Gordo; Núria Díez-Padrisa; Fatima Abacassamo; Pilar Pérez-Breña; Inmaculada Casas; Pedro L Alonso; Anna Roca Journal: Trop Med Int Health Date: 2011-06-28 Impact factor: 2.622
Authors: Frank F A IJpma; Dennis Beekhuis; Mark F Cotton; Clarissa H Pieper; Jan L L Kimpen; Bernadette G van den Hoogen; Gerard J J van Doornum; D M E Osterhaus Journal: J Med Virol Date: 2004-07 Impact factor: 2.327
Authors: Lisa M McNally; Prakash M Jeena; Kavitha Gajee; Stanley A Thula; A Willem Sturm; Sharon Cassol; Andrew M Tomkins; Hoosen M Coovadia; David Goldblatt Journal: Lancet Date: 2007-04-28 Impact factor: 79.321
Authors: Daniel R Feikin; M Kariuki Njenga; Godfrey Bigogo; Barrack Aura; George Aol; Allan Audi; Geoffrey Jagero; Peter Ochieng Muluare; Stella Gikunju; Leonard Nderitu; Amanda Balish; Jonas Winchell; Eileen Schneider; Dean Erdman; M Steven Oberste; Mark A Katz; Robert F Breiman Journal: PLoS One Date: 2012-08-24 Impact factor: 3.240
Authors: A C Pecego; R T Amâncio; D M Costa; F A Bozza; M M Siqueira; M L Oliveira; J Cerbino-Neto; A Japiassu Journal: Int J STD AIDS Date: 2020-01-22 Impact factor: 1.359
Authors: Everlyn Kamau; John W Oketch; Zaydah R de Laurent; My V T Phan; Charles N Agoti; D James Nokes; Matthew Cotten Journal: BMC Genomics Date: 2020-01-02 Impact factor: 3.969